About this white paper
Key topics covered in this resource
Since the implementation of the revised EU GMP Annex 1, regulatory scrutiny of sterile manufacturing has intensified worldwide.
This white paper analyses 230 FDA warning letters and identifies recurring deficiencies that directly relate to Annex 1 contamination control principles.
Rather than isolated technical issues, many inspection findings reveal systemic weaknesses in contamination control strategies and Pharmaceutical Quality System governance.
What you'll learn
Key takeaways from this document
In this white paper, you'll discover:
- The most common sterile manufacturing deficiencies observed in FDA warning letters
- How these observations relate to EU GMP Annex 1 requirements
- The eight recurring compliance domains affecting sterility assurance
- Practical insights to strengthen contamination control and inspection readiness
About the Author
Division Head Qualification/Validation
Jo Doucet is an expert in qualification and validation with over 20 years of experience in the pharmaceutical industry. He leads the Qualification/Validation division at QbD Group, supporting teams and clients in GxP compliance projects across manufacturing, IT, QC, and medical devices.
About the Author
